Extending natalizumab up to 8 weeks shown safe and effective in patients with MS

Infusion medication was well-tolerated for up to 8 weeks, double standard dose schedule

2015-04-20

(Press-News.org) In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy (PML). The drug showed similar efficacy in treating disease activity among patients, according to the study led by Lana Zhovtis-Ryerson, MD, an assistant professor of neurology at the NYU Langone Multiple Sclerosis Comprehensive Care Center. The findings were presented at the American Academy of Neurology Annual Meeting held April 18-25, in Washington, D.C. Natalizumab is an infusion drug known as a monoclonal antibody that is used to prevent MS symptoms and flare-ups and slow worsening disability. However, taking the medication longer than two years may increase risk for a rare but potentially fatal side effect called PML, an untreatable brain infection caused by the JC virus that occurs in up to 1.3 percent of patients taking natalizumab. The medication is typically prescribed in 300-milligram infusions every four weeks. "There remains much unknown about whether the drug will lose effectiveness if dosing is extended," explains Dr. Zhovtis-Ryerson. "Our study showed treatment with natalizumab was safe for patients with similar efficacy reported as the standard dosing, potentially enabling patients to stay on effective MS medication at a reduced frequency of infusions and with lower risk of PML. " Zhotvis-Ryerson and colleagues at 10 U.S. M.S. Centers sought to compare the safety and efficacy of an extended dose of natalizumab to the standard dose. They retrospectively compared 1,078 patients taking a standard 4-week dose to 886 taking an extended dose between 4 weeks, 3 days and 8 weeks, 5 days. The researchers found extending the dosing schedule of natalizumab to between 5 and 8 weeks does not affect the drug's efficacy profile with 65 percent of participants in each group not showing clinical MS activity, and comparable rates of new lesions reported on imaging. Zero cases of PML were reported in the extended dosing group, while two cases were reported in the standard dose group, though the researchers said statistical significance has not been reached yet. No other major adverse events were reported. "While the findings are encouraging, more research is needed to determine whether extending natalizumab dosing may reduce disability progression," says Dr. Zhovtis-Ryerson. Natalizumab is manufactured by Biogen Idec and Elan, and sold under the name Tysabri.

INFORMATION:

No grant or industry support was used for this study. Dr. Zhovtis has received compensation from Biogen Idec and Teva for research and for participation in the speaker bureau.

In addition to Dr. Zhotvis-Ryerson, the study's co-authors are: Lana Zhovtis Ryerson, Joseph Herbert, John Foley, Bianca Weinstock-Guttman, Carlo Tornatore, Siddharama Pawate, Roberto Bomprezzi, Krupa Pandey, Derek Smith, Ilya Kister, David Hojnacki, Gina Remington, Channa Kolb, Meg Bucello, Teresa C. Frohman, Darin Okuda, Zoe Rimler, Julia Fallon, Jennifer Kalina, Tammy Hoyt, Michael Bradshaw, Eric Chamot, Eugene Major, Daniel Douek, Elliot Frohman

[P3.267] Safety and Efficacy of Extended Dose Natalizumab in Multiple Sclerosis: An Ongoing Multicenter Study. Session: P3: Poster Session III: MS and CNS Inflammatory Diseases: Treatment Efficacy, Safety and Tolerability (2:00 PM-6:30 PM)?Date/Time: Tuesday, April 21, 2015 - 2:00 pm

ELSE PRESS RELEASES FROM THIS DATE:

Research highlights the importance of 'self-DNA' for maintaining diversity among species

2015-04-20

In natural plant communities, diversity is maintained by limits set on each plant by itself. This involves a detrimental effect of self-DNA (DNA from the same species released during decomposition) on the plant's and its offspring's growth. New research finds that this process not only regulates plant populations but may also be generalized to a range of additional organisms including algae, protozoa, fungi, and animals. The findings indicate that self-DNA is involved in the regulation of species coexistence and competition, and it might be harnessed for new pharmacological ...

Smoking may affect some women's likelihood of giving birth to twins

2015-04-20

A new study provides a possible explanation of reports that mothers of twins are more likely to have smoked, despite evidence that nicotine reduces fertility. Nicotine has an effect on hormone production, and while smoking may have deleterious effects on fertility, the study found that it may raise the likelihood of producing twins in women with certain genetic backgrounds. The researchers discovered significant interactions between smoking and variants in several genes, especially one in the TP53 gene. "Although we demonstrated that there are significant differences ...

What's the life expectancy of patients when they begin treatment for osteoporosis?

2015-04-20

Despite reports that people with osteoporosis have an increased risk of dying prematurely, a new study has found that life expectancy of newly diagnosed and treated osteoporosis patients is in excess of 15 years in women below the age of 75 and in men below the age of 60. In more detailed analyses, the residual life expectancy after beginning osteoporosis treatment was estimated to be 18.2 years in a 50-year-old man and 7.5 years in a 75-year old man. Estimates in women were 26.4 years and 13.5 years. The Journal of Bone and Mineral Research study included 58,637 patients ...

Vitamin D deficiency common in patients with lung disease

2015-04-20

A new study from Korea has uncovered a high prevalence of vitamin D deficiency in individuals with chronic obstructive pulmonary disease (COPD), as well as a significant relationship between vitamin D deficiency and airflow limitations. Exercise capacity also tended to be decreased in participants with vitamin D deficiency. "About 80% of the 193 patients with COPD in the study had vitamin D deficiency compared with 40% to 60% of Koreans in the general population," said Dr. Sang-Do Lee, senior author of the Respirology study. INFORMATION: ...

Addressing the needs of young women with disorders of sex development

2015-04-20

Disorders of sex development are lifelong conditions that are usually diagnosed at birth or during adolescence. In a recent study of 13 teenaged girls with disorders of sex development, the girls were guarded and reticent about sharing personal information about their disorder during adolescence, but some of them learned to engage in conversations with more confidence as they moved towards adulthood. The participants noted that frustrations about their bodily differences and the limitations of their bodies limited physical spontaneity, impacted on their perceived sexual ...

Interventions developed at Johns Hopkins reduce bloodstream infections in Abu Dhabi

2015-04-20

A bundled intervention focused on evidence-based infection prevention practices, safety culture and teamwork, and scheduled measurement of infection rates considerably reduced central line-associated bloodstream infections (CLABSIs) across intensive care units (ICUs) in seven Abu Dhabi hospitals, researchers from the Johns Hopkins Armstrong Institute for Patient Safety and Quality report. The intervention, undertaken by 18 ICUs, achieved an overall 38 percent reduction in these infections; and the number of units with a quarterly CLABSI rate of less than one infection ...

PTSD common in ICU survivors

2015-04-20

Fast Facts Research finds that one-quarter of patients who survive a critical illness and an ICU stay experience PTSD. Researchers are looking into using ICU diaries as a promising therapeutic tool to prevent PTSD in ICU survivors. Existing psychological problems, large amounts of sedation and reports of frightening ICU memories appear to contribute to the increased risk of PTSD in ICU survivors. Post-traumatic stress disorder is often thought of as a symptom of warfare, major catastrophes and assault. It's rarely considered in patients who survive a critical ...

Providing universal donor plasma to massively bleeding trauma patients

2015-04-20

A recent randomized trial that looked at the feasibility of 2013 guidelines issued by the American College of Surgeons Trauma Quality Improvement Project for trauma resuscitation found that delivering universal donor plasma to massively hemorrhaging patients can be accomplished consistently and rapidly and without excessive wastage in high volume trauma centers. The plasma is given in addition to red blood cell transfusions to optimize treatment. The 2013 guidelines recommend that universal donor products be immediately available on arrival of severely injured patients, ...

Study sheds new light on a crucial enzyme for the immune response

2015-04-20

Montréal, April 20, 2014 - A new study by immunology researchers at the IRCM led by Javier M. Di Noia, PhD, sheds light on a mechanism affecting AID, a crucial enzyme for the immune response. The scientific breakthrough, published in the latest issue of The Journal of Experimental Medicine, could eventually improve the way we treat the common flu, as well as lymphoma and leukemia. The researchers study white blood cells, called B-lymphocytes, whose main function is to produce antibodies to fight against infections. More specifically, they focus on an enzyme found ...

Atrial fibrillation recurrence lower with sleep apnea treatment

2015-04-20

WASHINGTON (April 20, 2015) - The use of continuous positive airway pressure was associated with a significant reduction in the recurrence of atrial fibrillation in patients with obstructive sleep apnea, according to an analysis of data from past research published today in the Journal of the American College of Cardiology: Clinical Electrophysiology. Researchers from the New York University Langone Medical Center in New York City performed a meta-analysis of seven studies including 1,087 patients to determine if continuous positive airway pressure (CPAP) reduced the ...

Extending natalizumab up to 8 weeks shown safe and effective in patients with MS

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: